Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00417794
Other study ID # 2115
Secondary ID
Status Completed
Phase Phase 1
First received January 2, 2007
Last updated April 6, 2017
Start date August 2005
Est. completion date April 22, 2015

Study information

Verified date April 2017
Source University of Oklahoma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if atomoxetine hydrochloride improves inattention, hyperactivity, and impulsivity problems in children exposed to alcohol during birth.


Description:

Abnormalities of attention, function, and activity level in children exposed to alcohol in utero share similarities and differences to children who do not have alcohol exposure. Previous psychological studies have examined either core attention deficit hyperactivity disorder (ADHD)symptoms of hyperactivity, inattention, and impulsivity or hypothesized neuropsychological differences in children with fetal alcohol syndrome (FAS) and ADHD. Atomoxetine Hydrochloride is a non-stimulant medication used to treat ADHD. This study will determine if atomoxetine HCL significantly reduces symptoms of ADD/ADHD in children with fetal alcohol exposure.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date April 22, 2015
Est. primary completion date April 22, 2015
Accepts healthy volunteers No
Gender All
Age group 4 Years to 11 Years
Eligibility Inclusion Criteria:

- Patient must be between the ages of 4 and 11 years at the time of entry into the study.

- Patients must meet diagnostic criteria for FASD

- Patient must meet DSM-IV criteria for ADHD, any subtype and must have an ADHDRS-IV score of > or = to 90%ile for age and gender for either subtest or total score if greater than 5 years of age.

- Patients who enter the study at visit 1 taking stimulant medication must be medication-free for at least 24 hours before visit 2.

- History and physical exam must reveal no clinically significant abnormalities that would preclude safe participation in the study.

- Patients must be able to swallow capsules.

- Patients must be of a sufficient developmental level (~3 yrs) to participate in the study.

- Patients and parents must be able to communicate effectively with the investigator and coordinator and be judged reliable to keep appointments and participate in data collection.

- Teacher must agree to cooperate with the study. Children less than 6 years old must have completed a course of PCIT and still meet DSM-IV criteria for ADHD.

Exclusion Criteria:

- Have received an in investigational medication in the past 30 days.

- Are currently on a medication treatment that is effective (ADHDRS-IV score within 1 SD of average) and well tolerated.

- Have significant current medical conditions that could be exacerbated or compromised by atomoxetine.

- Have used MAOIs within one month prior to visit 2.

- Patients with hypertension.

- Patients with a previous diagnosis of bipolar disorder, psychosis, or autism spectrum disorder.

- Patients taking anticonvulsants for seizure control.

- Patients taking another psychotropic medication or health food supplements purported to have central nervous system activity within 5 half-lives of visit 2.

- Patients with Tourette Disorder or any other neurological condition that would interfere with their ability to receive treatment or comply with monitoring.

- Pubertal girls.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Strattera
escalating dosage: 0.5 mg/kg, 1.0 mg/kg, and 1.4 mg/kg titrated up or down according to adverse effects to therapy
Placebo
0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.

Locations

Country Name City State
United States OU Child Study Center Oklahoma City Oklahoma

Sponsors (3)

Lead Sponsor Collaborator
University of Oklahoma Eli Lilly and Company, Mark L. Wolraich, M.D.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary ADHD Rating Scale - IV length of protocol
Secondary Determine if atomoxetine is safe and well tolerated by children with FAS. length of protocol
Secondary Determine if atomoxetine is effective in both school and home, and significantly reduces symptoms of inattention, hyperactivity, and impulsivity in children with FAS compared to children with FAS receiving placebo. length of protocol
Secondary Determine if atomoxetine improves behaviors in the mornings and evenings. Length of protocol
Secondary Determine if parents of children with FAS are satisfied with the effectiveness of atomoxetine. Length of protocol
Secondary Determine if there are any differences in the adverse effects profile of children with FAS compared to the overall profile for atomoxetine. Length of protocol
Secondary Determine the degree of functional limitation experienced by this group of children with FAS and whether this impairment is decreased by treatment with atomoxetine as demonstrated by the Pediatric Evaluation of Disability Inventory (PEDI) Length of protocol
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Active, not recruiting NCT00996528 - Neighborhood Alcohol & HIV Prevention in South African Townships (Philani) Phase 3
Completed NCT00164229 - Fetal Alcohol Syndrome: Socio-Cognitive Habilitation Phase 1/Phase 2
Completed NCT00164554 - Fetal Alcohol Syndrome/ARND Research Consortion Phase 1/Phase 2
Recruiting NCT05534568 - The Oklahoma Parent-Child Assistance Program N/A
Recruiting NCT05385328 - Multisensorial Analysis of Human Activity for Diagnosis and Early Detection of Functional Limitations
Completed NCT01911299 - Choline Supplementation in Children With Fetal Alcohol Spectrum Disorders Phase 2
Terminated NCT00747630 - Evaluating the Efficacy of a Video Based Intervention to Educate Teen Moms About Fetal Alcohol Syndrome (FAS) Phase 0
Recruiting NCT04332172 - Scaling Up: A Multi-Site Trial of e-SBI for Alcohol Use in Pregnancy N/A
Completed NCT00696085 - Fetal Alcohol Damage Prevention Study N/A
Recruiting NCT00418262 - Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD Phase 3
Completed NCT01149538 - Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure Phase 1/Phase 2
Recruiting NCT03371641 - In Utero Alcoholic Exposure: PlGF, Biomarker of Fetal Brain Lesions N/A
Completed NCT00164346 - Neurocognitive Habilitation for Children With Fetal Alcohol Syndrome (FAS)/Alcohol-Related Neurodevelopmental Disorder (ARND) Phase 1/Phase 2
Completed NCT01994603 - Expansion to Interdisciplinary HIV Prevention in Women N/A
Completed NCT02600624 - Prenatal Alcohol Biomarker Study in Uruguay
Completed NCT00244062 - Healthy Moms Alcohol Intervention N/A
Recruiting NCT04395196 - RCT of Prenatal Choline Supplementation During Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure Phase 2